Peptide Romania
immunity

LL-37

Cathelicidin-derived antimicrobial peptide studied across infection and inflammation research.

Dovezi
Emerging
T½
Tissue-dependent
Categorie
immunity
Status
Investigational

Evaluarea dovezilor

Baza de dovezi

Emerging33%

Strong: Multiple studii umane controlate cu rezultate consistente și replicate de grupuri independente de cercetare.

Moderate: Studii umane sau animale cu semnale pozitive; există variabilitate metodologică sau date conflictuale limitate.

Emerging: Cercetare timpurie, predominant preclinică, cu rezultate promițătoare. Confirmarea umană este limitată.

Preliminary: Date foarte limitate, în principal rapoarte exploratorii sau studii singulare fără replicare independentă.

Farmacologie

Mecanism de acțiune

Cathelicidin-derived antimicrobial peptide studied across infection and inflammation research.

T½Tissue-dependent
StatusInvestigational
Categorieimmunity
DoveziEmerging

Întrebări frecvente

Ce trebuie să știi

Cathelicidin-derived antimicrobial peptide studied across infection and inflammation research.
LL-37 has Emerging evidence. Early-stage research, mostly preclinical, shows promising preliminary results. Human confirmation is limited — findings should be interpreted cautiously by researchers.
The half-life of LL-37 is Tissue-dependent. This determines dosing frequency in research protocols — shorter half-lives require more frequent administration to maintain stable concentrations in study subjects.
LL-37 is currently classified as: Investigational. Regulatory status varies by jurisdiction — always consult local regulations and a qualified medical professional before any use outside an approved clinical context.
Cathelicidin-derived antimicrobial peptide studied across infection and inflammation research.
Înapoi la peptide